Clinical Trial Update: Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial investigating androgen suppression and radiation with or without docetaxel in high-risk localized prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED